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Background and purpose — The bone cement market for total 
knee arthroplasty (TKA) in Norway has been dominated by a few 
products and distributors. Palacos with gentamicin had a market 
share exceeding 90% before 2005, but it was then withdrawn 
from the market and replaced by new slightly altered products. 
We have compared the survival of TKAs fi xated with Palacos 
with gentamicin with the survival of TKAs fi xated with the bone 
cements that took over the market.
Patients and methods — Using data from the Norwegian Arthro-
plasty Register for the period 1997–2013, we included 26,147 pri-
mary TKAs in the study. The inclusion criteria were TKAs fi xated 
with the 5 most used bone cements and the 5 most common total 
knee prostheses for that time period. 6-year Kaplan-Meier sur-
vival probabilities were established for each cement product. The 
Cox proportional hazards regression model was used to assess 
the association between bone cement product and revision risk. 
Separate analyses were performed with revision for any reason 
and revision due to deep infection within 1 year postoperatively 
as endpoints. Adjustments were made for age, sex, diagnosis, and 
prosthesis brand.
Results — Survival was similar for the prostheses in the follow-
up period, between the 5 bone cements included: Palacos with 
gentamicin, Refobacin Palacos R, Refobacin Bone Cement R 
(Refobacin BCR), Optipac Refobacin Bone Cement R (Optipac 
Refobacin BCR), and Palacos R+G. 
Interpretation — According to our fi ndings, the use of the new 
bone cements led to a survival rate that was as good as with the 
old bone cement (Palacos with gentamicin). 
■
Fixation methods for total knee arthroplasty (TKA) implants 
are cemented, cementless, or a combination (hybrid). The 
majority of TKAs performed in Scandinavia are cemented 
(Robertsson et al. 2010). Aseptic loosening of the primary 
TKA is the most common reason for revision (Carr et al. 2012, 
Furnes et al. 2014).  
The acrylic bone cements are regulated by 2 international 
standards (Nottrott 2010), with current versions ISO-5833-
2002 and ASTM F451-08. Complying with the requirements 
of the standards, which are based on preclinical testing, does 
not seem to guarantee clinical success. In the past, there have 
been examples of poor clinical performance of some of the 
approved bone cements (Espehaug et al. 2002). The bone 
cement Boneloc is perhaps the most prominent case. This 
product was introduced in the early 1990s, but was withdrawn 
from the market already in 1995. Short-term studies had 
revealed poor clinical performance compared to conventional 
acrylic bone cements (Havelin et al. 1995, Suominen 1995, 
Thanner et al. 1995, Furnes et al. 1997, Markel et al. 2001). 
Generally speaking, the regulatory framework worldwide for 
medical devices including implants and bone cements has 
been much less rigorous than that for new drugs (Riehmann 
2005, Carr et al. 2012, Labek et al. 2015).
Approximately 20 bone cement products used for TKAs 
have been reported in the Norwegian Arthroplasty Register 
(NAR). Even so, only 5 different high-viscosity polymethyl-
methacrylate (PMMA) bone cement products with antibiotics 
have been used in over 90% of all the reported TKAs (Furnes 
et al. 2014). 
Before 2004, Palacos with gentamicin (Schering-Plough) 
had a market share of approximately 90% in Norway. This 
product was the result of a collaboration between Heraeus 
Kulzer, who produced the cement components, and Schering-
Plough, who supplied and added the antibiotic gentamicin. The 
distributor of the end-product in Scandinavia was Schering-
Plough. This bone cement product was seen by many orthope-
dic surgeons to be the gold standard in this area. In other parts 
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of Europe, Heraeus Kulzer had a collaboration with Merck, 
and the end-product was distributed by Merck under the name 
Refobacin Palacos R (Kühn 2000). In 1998, Biomet entered 
a joint venture with Merck, and in 2004 they purchased Mer-
ck’s interest, and founded the Biomet Europe Group. Then, 
in 2005, Heraeus Kulzer decided to self-distribute the bone 
cement end-product to all territories, and the well-known 
products Palacos with gentamicin and Refobacin Palacos R 
were removed from the market (Bridgens et al. 2008, Neut 
et al. 2010). Heraeus Kulzer and Biomet then introduced the 
new products Palacos R+G and Refobacin BCR, respectively. 
Both of the companies, Biomet and Heraeus Kulzer, have 
claimed in the past that their new products are equivalent to 
their predecessor (Neut et al. 2010, KOFA 2011). On the other 
hand, it has been shown that even small differences in process-
ing and source of substances may infl uence the end-product, 
for example the release of gentamicin (Kühn 2000). A number 
of in vitro studies also brought to light various minor differ-
ences between the old and new products in the years that fol-
lowed (Dall et al. 2007a and b, Bridgens et al. 2008, Kock et 
al. 2008, Neut et al. 2010).  
With this background, and using data from the NAR, we 
compared the survival of TKAs fi xated with the old Palacos 
with gentamicin and that of TKAs fi xated with the most used 
bone cement products that took over the market. We also stud-
ied deep infection up to 1 year postoperatively, which would 
include both early postoperative infections and most of the 
late chronic infections (Tsukayama et al. 1996).    
Patients and methods
The data were taken from the Norwegian Arthroplasty Reg-
ister (NAR), a national registry covering Norway’s approxi-
mately 5 million inhabitants, which was founded in 1987 as a 
hip registry (Havelin et al. 2000). In 1994, knee arthroplasty 
was included in the registry (Furnes et al. 2002), and by the 
end of 2013 approximately 50,000 TKAs had been registered. 
For the period 1999–2002, 99% of all TKAs and 97% of all 
TKA revision operations in Norway were reported to the reg-
ister (Espehaug et al. 2006). For the period 2008–2012, an 
external analysis found a completeness of more than 95% for 
primary TKA operations and of 89% for TKA revision opera-
tions (Furnes et al. 2014). The information from each opera-
tion is reported using a standardized form fi lled out by the 
surgeon on a voluntary basis, and sent by post to the registry. 
The information collected in the registry includes the date of 
the operation, the civil registration number of the patient, indi-
cation for the procedure, bone cement product (as identifi ed 
by catalogue numbers from stickers in the cement wrapping), 
hospital, and prosthesis brand at the catalogue number level. 
The NAR publishes annual reports with descriptive statistics 
(http://nrlweb.ihelse.net). 
Study sample
47,503 TKAs were reported to the NAR in the period from 
January 1, 1997 to December 31, 2013. We excluded TKAs 
with patellar component (n = 3,205), with unknown diagnosis 
(n = 103), those uncemented/fi xated without antibiotic-loaded 
bone cement (n = 2,605), and those with unequal proximal and 
distal bone cement (including hybrid prostheses) (n = 6,018). 
Figure 1 shows a breakdown of the bone cements used in the 
remaining TKAs.
In addition, we excluded bone cements used for less than 
3 years and in less than 1,000 knees in total (n = 2,846). 
The remaining bone cements were: Palacos with gentamicin 
(Schering-Plough), Palacos Refobacin R (Merck), Palacos 
R+G (Heraeus Kulzer/Heraeus Medical), Refobacin BCR 
(Biomet), and Optipac Refobacin BCR (Biomet).  
TKAs with unequal prosthesis type in the proximal and 
distal part, or with missing information, were excluded (n = 
508). Furthermore, only TKAs with prosthesis brands used 
over the whole study period (1997–2013) and in over 2,000 
knees were included. These criteria left Profi x (Smith and 
Nephew), LCS/LCS Complete (DePuy), AGC (Biomet), and 
NexGen (Zimmer,) and led to exclusion of 6,057 TKAs. For 
each of the bone cements, a specifi c time interval for inclusion 
was defi ned, leading to exclusion of 14 other TKAs.
These exclusion/inclusion criteria were used to make the 
study population as homogeneous as possible regarding the 
infl uence of the bone cement product. Maximum possible 
follow-up was 9 years for the different bone cements, except 
for Optipac Refobacin BCR, which had only been in use for 6 
years (since 2008). 
We identifi ed 26,147 TKAs in the total study population 
for comparison of survival rate according to the bone cement 
products (Table 1 and Figure 2). 
In this study, some patients received 2 TKAs and the study 
population consisted of 20,979 individuals. 
Outcome
The outcome variable was prosthesis survival, defi ned as 
time from implantation to revision. Revision was defi ned as 
exchange, or addition or removal of the implant or part of the 
implant. Observation times were censored at time of death, 
emigration, or end of study. Information on death and emi-
gration was obtained from the National Population Registry 
(TaxAdmin 2014) using the civil registration numbers of Nor-
wegian residents.
Predictor
Bone cement product (Palacos with gentamicin, Refobacin 
Palacos R, Refobacin BCR, Optipac Refobacin BCR, and Pal-
acos R+G) was evaluated as a predictor of prosthesis survival.
Other variables
Adjustment was performed for possible confounding by age 
(< 60, 60–69, 70–79, > 79), sex, diagnosis (arthrosis, other), 
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and prosthesis brand (LCS/LCS Complete, AGC, NexGen, 
Profi x).
Statistics
6-year survival probabilities with 95% confi dence intervals 
(CIs) were established for each bone cement product using 
the Kaplan-Meier method. Any p-values < 0.05 were consid-
ered statistically signifi cant. We used the Cox proportional 
hazards regression model to assess the association between 
cement product and revision risk. Unadjusted and adjusted 
relative revision risk (RR) estimates were established for each 
bone cement relative to the Palacos R+G, and are presented 
with CIs and p-values. We also calculated p-values for tests 
of the overall impact on survival of the cement product. Sur-
vival curves were constructed based on the adjusted estimates, 
and stratifi ed for the different bone cements to illustrate pos-
sible differences in the distribution of time from insertion of 
the prosthesis to revision. Separate analyses were performed 
with revision for any reason and revision due to deep infection 
within 1 year postoperatively, as endpoints.  The proportional 
hazards assumption of the Cox model was investigated visu-
ally and tested based on scaled Schoenfeld residuals (Ranstam 
et al. 2011), and found to be valid for cements in the analyses 
with revision for any reason as endpoint (all p > 0.3). With 
revision due to deep infection within 1 year as endpoint, the 
assumption was violated for 2 cement products: Palacos with 
gentamicin (p < 0.001) and Optipac Refobacin BCR  (p = 
0.03).  The residual plot (not shown) and the reported survival 
curves indicated that analyses performed for different follow-
up periods were unlikely to change our conclusions. 
Table 1. Inclusion criteria for bone cements and prostheses with product information 
Inclusion Products
criteria included Distributor Comments
Cements 
 Used > 3 years. Used in over 1,000 knees. Equal bone cement in proximal and distal part of prosthesis 
  Palacos with Schering-Plough a The cement components (poly/monomers) was produced by Heraeus Kulzer
     gentamicin   and antibiotics were added by Schering-Plough. The single most used cement
    before 2005, and considered as the gold standard for many years. Mostly used in 
    Scandinavia. Also referred to as Palacos R with gentamicin or Palacos R40G in 
    some papers. Withdrawn from the market in 2005.
  Palacos  Merck  Identical cement components (poly/monomers) as in Palacos with gentamicin.  
  Refobacin R   Antibiotics added under license from Merckby Heraeus Kulzer, and end product 
    distributed by Merck b. Withdrawn from the market in 2005.
   Palacos R+G Heraeus Kulzer c The cement components (poly/monomers) are identical to those in Palacos with
    gentamicin.  New vendor for gentamicin. Minor differences in production method
    for the addition of the gentamicin.
  Refobacin BCR Biomet d Copy product of the old “Palacos” cement. New vendor of cement monomers/
     polymers. Antibiotics added with the same procedure as in Palacos Refobacin R.  
  Optipac  Biomet d Identical components as Refobacin BCR, but all ingredients come
  Refobacin BCR  pre-packaged in a mixing system, which remains closed until the cement is appl 
Prostheses  
 Used in the whole study period (1997–2013). Used in over 2,000 knees. Equal prosthesis proximally and distally.
  Profi x  Smith and Nephew Cruciate retaining. 
  LCS DePuy Mobile bearing. LCS was used until 2006.
  LCS Complete DePuy Mobile bearing. Assessed as same prosthesis as LCS in this paper, due to the 
    similarities. Used from 2003.
  AGC  Biomet  Cruciate retaining. 
  NexGen  Zimmer Cruciate retaining.
a Merged with Merck & Co. in 2009
b Later Biomet-Merck
c Heraeus Medical from year 2009 (company re-organization)
d Zimmer Biomet from year 2015
Figure 1. Bone cements used for TKAs in Norway in the period 1997–
2013. TKAs with patellar component, unknown diagnosis, fi xation 
without antibiotic-loaded bone cement, and hybrid fi xation (or unequal 
bone cement in distal and proximal part) are not included.
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Statistical analyses were performed using the software 
SPSS Statistics version 22.  
Results
None of the bone cements had been used over the entire study 
period. Palacos R+G was the most frequently used bone 
cement (used in 8,278 knees). Refobacin Palacos R was used 
in 1,206 knees and was the least used; it also had the short-
est period of time in use (3 years). The 
distribution of age was homogenous for 
the different cements, with most patients 
between 60 and 80 years of age. The least 
used prosthesis/cement combination was 
the NexGen prosthesis in combination 
with the cement Palacos with gentamicin 
(138 knees). The most frequent combi-
nation was Optipac Refobacin BCR with 
LCS Complete (3,304 knees). Over 85% 
of all the TKAs were done because of 
osteoarthritis. 75 different hospitals had 
performed TKAs, and 61 of them had 
used more than 1 cement product (Table 
2 and Figure 2).
Survival
All the bone cements had almost identi-
cal results (p = 0.9) with an unadjusted 
survival percentage of approximately 
95% at 6 years. Similar fi ndings were 
obtained with adjustment for differences 
in age, sex, diagnosis, and prosthesis 
brand (p = 0.4) (Table 3 and Figure 3). 
Infection
Within one year postoperatively, 147 
revisions were done due to deep infec-
tion. Compared to Palacos R+G, Pala-
cos with gentamicin had a statistically 
signifi cantly lower risk of revision due 
to infection (RR = 0.5, CI: 0.3–0.8; p 
= 0.01). There were no statistically sig-
nifi cant differences between the 3 bone 
cements that are currently on the market 
(p = 0.7) (Table 4 and Figure 4).     
Discussion
Summary
We found no statistically signifi cant dif-
ferences in TKA survival for the bone 
cements Palacos with gentamicin, Refo-
Table 2. Patient and procedure characteristics for the different bone cement products
 
Variables Palacos with Refobacin Palacos Refobacin Optipac
  gentamicin Palacos R R+G BCR Refobacin BCR  Total
      
TKAs 7,650 1,206 8,278 4,505 4,508 26,147
Proportion of total, %  29 5 32 17 17 100
Males, % 29 31 35 35 37 33
Age in years, %      
    < 60 15 15 17 18 18 16
    60–69 27 29 34 34 36 32
    70–79 43 41 36 35 36 38
    > 79 15 15 14 13 10 14
Prosthesis, %      
    AGC 22 20 6 28 9 15
    NexGen 2 9 15 8 11 9
    Profi x 40 39 52 16 7 34
    LCS/LCS complete 36 33 27 48 73 42
Diagnosis, %      
    Osteoarthritis 85 89 88 88 91 88
    Other 15 11 12 12 9 12
No. of hospitals 65 33 52 40 29 75
Excluded TKAs:
– TKAs with patellar component, 3,205
– TKAs with unknown diagnosis, 103
– TKAs with uncemented/antibiotic free cement, 2,605
– TKAs with hybrid fixation or unequal bone cement
   in distal and proximal part, 6018
Study population for evaluation

















n = 35,572 a
Excluded TKAs:
– TKAs with bone cements not included in the study, 2,846
– TKAs with missing prosthesis information or unequal
   proximal and distal prosthesis type, 508
– TKAs with prostheses not included in the study, 6,057
– TKAs with the included bone cements, but use of them 
   outside the defined time periods, 14
Primary TKAs reported to
NAR between 1997 and 2013
n = 47,503
bacin Palacos R, Palacos R+G, Refobacin BCR, and Optipac 
Refobacin BCR. Palacos with gentamicin had a signifi cantly 
lower risk of infections than Palacos R+G. The bone cements 
currently on the market had practically the same risk of infec-
tion 1 year postoperatively. 
Other relevant studies
Olerud et al. (2014) performed a consecutive radiostereomet-
ric study comparing Refobacin BCR cement with Palacos with 
gentamicin, which were used in total hip arthroplasty (THA) 
Figure 2. The selection procedure from the data registered in the NAR. n = number of knees 
with TKA. a Illustrated in Figure 1.b The time period of use included in study.   
Acta Orthopaedica 2017; 88 (1): 75–81 79
for 2 patient groups. They studied 51 patients, observing them 
for 2 years. They found no clinical or statistically signifi cant 
difference between the 2 cements, and concluded that Refo-
bacin BCR should be safe for clinical use in THAs. However, 
they also stressed the need for longer follow-up and for results 
from national registries. Limitations of their study included 
the short follow-up time (2 years), the lack of randomization, 
and the length of time between the 2 study groups (due to use 
of the bone cements in different time periods). Their results 
may not be transferrable to TKAs.
Kock et al. (2008) conducted in vitro tests of different prop-
erties between the “Palacos” cements Refobacin Palacos R 
and Palacos R+G and the bone cements SmartSet GHV and 
Refobacin BCR. Their study included handling properties, 
chemical analysis, and testing according to the ISO standard 
for acrylic bone cements. Their fi ndings clearly indicated that 
the copolymers used in the cements SmartSet GHV and Refo-
bacin BCR were different from those used in the 2 “Palacos” 
cements. They also found differences in viscosity and waiting/
hardening times. Since the cement products clearly appeared 
to be dissimilar, they concluded that clinical data from long-
term use of the Palacos cements cannot be extrapolated to 
Refobacin BCR (and SmartSet GHV). 
Neut et al. (2010) compared in vitro gentamicin release 
from Refobacin Palacos R, Refobacin BCR, Palacos R+G, and 
SmartSet GHV. All the 3 newer cements showed higher sustained 
release of gentamicin compared to that from Refobacin Palacos 
R. They therefore concluded that the gentamicin release charac-
teristics of the old and new cements were different. 
Table 3. Cox relative revision risk (RR) estimates with revision for any reason as endpoint. Unadjusted and adjusted for age, sex, diagnosis, 
and prosthesis brand
  Median Maximum     Unadjusted Adjusted 
    follow-up, follow-up, No. No. at risk, Kaplan-Meier survival
Bone cement years years revised   6 years at 6 years (95% CI) RR (95% CI) RR (95% CI) p-value
Palacos R+G 3.9 8.4 299 2,034 95.2 (94.6–95.7) 1 (ref)                1 (ref) –
Palacos with gentamicin 2.9 9.0 259 821 94.9 (94.2–95.6) 1.00 (0.85–1.18) 0.98 (0.83–1.17) 0.9
Refobacin BCR 5.2 8.3 183 1,771 95.2 (94.5–95.9) 0.98 (0.82–1.18) 0.88 (0.73–1.06) 0.2
Optipac Refobacin BCR  2.2 6.0 120 a b 0.96 (0.78–1.19) 0.84 (0.67–1.05) 0.1
Refobacin Palacos R 7.7 9.0 53 1,020 95.5 (94.3–96.7) 0.88 (0.66–1.18) 0.86 (0.64–1.16) 0.3
a Last revision at 4.5 years; at risk: 339. 
b Last revision at 4.5 years; survival (95% CI): 95.3% (94.2–96.5).
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Figure 3. Cox survival curves with cement product as stratifi cation vari-
able for all TKAs with revision for any reason as endpoint. The curves 
were estimated with adjustment for age, sex, diagnosis, and prosthesis 
brand.
Figure 4. Cox survival curves with cement product as stratifi cation vari-
able for TKAs with revision due to deep infection within one year post-
operatively as endpoint. The curves were estimated with adjustment 
for age, sex, diagnosis, and prosthesis brand.
Table 4. Cox relative revision risk (RR) estimates with revision due to 
deep infection within 1 year postoperatively as endpoint. Adjusted 
for age, sex, diagnosis, and prosthesis brand 
   At risk, No. Adjusted
Bone cement 1 year revised  RR (95% CI) p-value
     
Palacos R+G 7,027 55 1 (ref) –
Palacos with gentamicin 6,812 26 0.52 (0.32–0.84) 0.01
Refobacin BCR 4,220 27 0.92 (0.56–1.50) 0.7
Optipac Refobacin BCR 3,975 32 1.18 (0.73–1.91) 0.5
Refobacin Palacos R 1,190 7 0.87 (0.39–1.92) 0.7
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Dall et al. (2007a) performed an in vitro comparison of 
mechanical and handling properties between Refobacin Pala-
cos R and the newer Palacos R+G and Refobacin BCR. All 
3 cements were found to have comparable mechanical prop-
erties, and to release similar amounts of gentamicin. On the 
other hand, they found different handling/viscosity curves for 
the different products, and concluded that these bone cements 
may perform differently in the operating theater from a sur-
geon’s point of view.
Dall et al. (2007b) also conducted a study assessing the 
inter-batch and intra-batch variability in the handling charac-
teristics and viscosity for the cements Refobacin BCR, Pala-
cos R+G, Simplex P Tobramycin, and SmartSet GHV. Refo-
bacin BCR was found to have a different viscosity from Pala-
cos R+G. Their results also suggested that extrinsic factors, 
such as preparation conditions, may be of more importance 
than intrinsic variability.
Bridgens et al. (2008) performed an in vitro study compar-
ing Palacos with gentamicin with the cements Palacos R+G 
and SmartSet GHV. All cements performed well, with minor 
differences. Regarding the difference between the old and new 
Palacos cements, they wrote: “We have also shown that the 
properties of Heraeus Palacos (meaning: Palacos R+G) com-
pared with Schering-Plough Palacos (meaning: Palacos with 
gentamicin) are different, with superior elution of antibiotics 
and mechanical characteristics shown by Heraeus Palacos”. 
Explanations and interpretation
All these studies indicated some minor differences between 
the old and new bone cements. The new bone cements are 
almost identical to the old ones, but the small differences may 
be due to new suppliers of monomers, copolymers, and genta-
micin—and/or slightly changed production procedures. Such 
minor changes in the chemical properties of the ingredients 
could affect the end-product (Kühn 2000, Milner 2004, Dall 
et al. 2007a and b). This explanation was also suggested by 
an offi cial statement from Heraeus Kulzer, given in Bridgens 
et al. (2008). Furthermore, a legal dispute between Heraeus 
Medical Nordic and Biomet at the Norwegian Complaints 
Board for Public Procurement regarding the procurement 
of cement has indicated that the suppliers of antibiotics and 
monomers, and also production methods, do actually vary to 
some extent between the old and new products (KOFA 2011).
Our study has shown that these minor changes did not infl u-
ence the clinical performance using survival of the TKAs as the 
outcome measure, but may have infl uenced other parameters. 
For example, several of the studies referred to suggest a pos-
sibly higher gentamicin release from the bone cements that are 
currently on the market (Bridgens et al. 2008, Neut et al. 2010). 
One hypothesis would be that these properties may lead to 
fewer deep infections and therefore less septic loosening/revi-
sion (Espehaug et al. 1997). The present study does not indicate 
that there may be any clinical effect of a possibly higher genta-
micin release. In fact, the old Palacos with gentamicin cement 
had a statistically signifi cantly lower deep infection rate than 
the new cements within 1 year postoperatively. We believe that 
this is a time-dependent effect, and a result of comparison of 
results from different time periods—as Palacos with gentamicin 
was stopped in 2005. Other registry-based studies have found 
an increased risk of revision due to deep infection from around 
year 2000, and especially after 2005, for THAs (Dale et al. 
2009, 2012). Possible explanations include change in reporting 
awareness, revision policy, selection of patients, more resistant 
bacteria, and more modular prostheses. The AGC prosthesis 
is non-modular, and was used more frequently in the “Palacos 
with gentamicin” era before 2005. All deep infections of the 
AGC knee may not have been captured due to the inclusion 
criteria for revision. The cements currently on the market had 
practically the same risk of infection 1 year postoperatively.  
Another parameter that may be altered is the preparation and 
the different phases during use (Kühn 2000). These properties 
are of importance to the operator. To our knowledge, almost 
all cements for TKAs in Norway are prepared with vacuum 
mixing systems in the operating theaters. The NAR does not 
have information on the mixing systems used, except for the 
pre-packaged systems. In our study, we included Optipac 
Refobacin BCR. This is the same bone cement as Refoba-
cin BCR, but it comes pre-packaged with a closed-vacuum 
mixing system.  Such products may have some advantages—
in, for example, reducing the risk of wrong preparation. In the 
present study, we found no statistically signifi cant differences 
between these 2 products.
Strengths and limitations
High-powered randomized clinical trials are seldom per-
formed for comparison of rare incidences, such as loosening 
of cemented TKAs. Large observational studies from arthro-
plasty registries may therefore provide a good alternative for 
the study of such events. 
The large number of TKAs assessed (26,147), and the fact 
that potential confounders had been adjusted for in the statisti-
cal models, is a strength of the study. Yet, survival of TKAs 
may also be confounded by other factors such as surgeon 
experience, patient comorbidities, temperature of the bone 
cement or of the operating theater, and the use of dissimilar 
vacuum mixing systems.
A limitation of the study was the short follow-up time. For 
the Boneloc cement, the chemical properties were dissimilar 
to those of the standard PMMA bone cements, and revisions 
started to appear after a short time (Suominen 1995, Havelin 
et al. 1995, Furnes et al. 1997, Markel et al. 2001). With only 
minor differences between the bone cements investigated in 
this study, any differences might therefore become apparent 
after a longer follow-up time.       
One fl aw might be that the change in the bone cement market 
in 2005 may have caused confusion for the reporting surgeons 
as well. All of sudden, the cements had a different name but 
had packaging of the same color. The registry may therefore 
Acta Orthopaedica 2017; 88 (1): 75–81 81
contain some minor errors from this period—if the surgeons 
reported the cement product in writing, instead of using the 
usual stickers delivered from the company as normally. 
Further research
Our study consisted of TKAs only. Whether our result can be 
extrapolated to—for example—THA remains to be investi-
gated. A longer follow-up period would also be desirable.  
Conclusion
We found no difference in prosthesis survival between the 
bone cement Palacos with gentamicin and the new products 
introduced after 2005, with this relatively short follow-up 
time. All the new bone cements included in this study appear 
to be as good as their predecessor. 
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